Welcome to our dedicated page for GENMAB A/S SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GENMAB A/S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GENMAB A/S's regulatory disclosures and financial reporting.
Genmab A/S has completed its share buy-back program, repurchasing 342,130 shares for a total of 615,105,001 DKK to meet commitments under its Restricted Stock Unit program. The program, launched on February 17, 2026, finished on March 13, 2026, earlier than expected.
From March 9 to March 13, 2026, Genmab bought 93,130 shares, including 25,130 shares on March 13 at an average price of 1,717.39 DKK. After these transactions, Genmab holds 2,859,663 treasury shares, representing 4.45% of its total share capital and voting rights.
Genmab A/S provides an update on its share buy-back program launched on February 17, 2026 to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to cover Restricted Stock Unit commitments. From March 2 to March 6, 2026, the company repurchased 101,000 shares for a total of DKK 180,733,150, bringing total repurchases under the program to 249,000 shares at a total value of DKK 452,588,620. Genmab corrects a previously reported “Accumulated through last announcement” figure, which should have been 63,000 shares, resulting in a corrected accumulated figure of 148,000 shares. After these transactions, Genmab holds 2,766,533 treasury shares, equal to 4.31% of its total share capital and voting rights.
Genmab A/S has furnished a Form 6-K for March 2026, primarily to submit its updated Articles of Association as Exhibit 3.1. The filing states that this report will be incorporated by reference into several existing Genmab Form S-8 registration statements and will form part of those documents from the filing date.
Genmab A/S filed a Form 6-K to share a company announcement correcting the reported price for recent insider equity awards. A prior notice had shown a share price of DKK 0.00 for transactions involving managerial employees and related persons; the correct price is DKK 1,867.50 per share.
The correction covers acquisitions of Genmab shares due to vesting of restricted stock units granted on February 24, 2023 to President & CEO Jan van de Winkel, EVP & CFO Anthony Pagano, and board members Mijke Zachariasse, Martin Schultz, and Michael Kavanagh. All transactions occurred outside the market and reflect routine equity compensation vesting rather than open-market trading.
Genmab A/S provides an update on its ongoing share buy-back program, which was initiated to repurchase up to 342,130 shares for a maximum of DKK 725 million to honor commitments under its Restricted Stock Unit program.
From February 23 to 27, 2026, Genmab repurchased 18,000, 12,000, 15,000, 20,000 and 20,000 shares on successive trading days, at average prices between DKK 1,825.23 and DKK 1,856.49, for total consideration of DKK 156,630,920 during this period and DKK 271,855,470 accumulated under the program. Following these transactions, Genmab holds 2,763,851 treasury shares, equal to 4.30% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K detailing new equity compensation grants and related insider transaction disclosures. The board granted 587,495 restricted stock units to management and employees and 455,004 warrants to employees of Genmab and its subsidiaries.
Each restricted stock unit is granted cost-free, represents a conditional right to one Genmab share of nominal DKK 1, and has a fair value equal to the grant-date closing share price of DKK 1,848.50. These RSUs generally vest three years after grant, with executive management awards linked to forward-looking performance criteria.
The warrants are also granted cost-free, have an exercise price of DKK 1,848.50 per share, a calculated fair value of DKK 594.08 using the Black-Scholes formula, vest after three years and expire seven years from grant. The filing also itemizes grants to key individuals, including CEO Jan G. J. van de Winkel and CFO Anthony Pagano, under market abuse regulation disclosure rules.
Genmab A/S filed a Form 6-K as a foreign private issuer for February 2026. The report primarily furnishes an updated corporate document, listing the company’s Articles of Association as Exhibit 3.1. The filing is also incorporated by reference into several existing Genmab Form S-8 registration statements.
Genmab A/S is making a small share capital increase after employees exercised warrants, issuing 12,313 new shares. The new shares were subscribed for cash at various prices between DKK 1,147.50 and DKK 1,615.00 per share, generating approximately DKK 17.1 million in proceeds for the company.
The new shares equal about 0.02% of Genmab’s existing share capital and carry the same rights as existing ordinary shares, including voting and dividend rights from subscription. After this increase, the total nominal share capital is DKK 64,250,721, corresponding to 64,250,721 shares and votes, and the new shares are expected to be listed on Nasdaq Copenhagen following registration.
Genmab A/S provides an update on its recently initiated share buy-back program. The company plans to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to meet obligations under its Restricted Stock Unit program, with completion expected by March 31, 2026.
From February 18 to February 20, 2026, Genmab repurchased 23,000, 25,000 and 15,000 shares, respectively, for a total consideration of DKK 115,224,550. Following these transactions, Genmab holds 2,678,851 treasury shares, representing 4.17% of its total share capital and voting rights.
Genmab A/S filed a Form 6-K reporting insider share trading by its Executive Vice President & Chief Financial Officer, Anthony Pagano. On February 19, 2026, he executed a sale of 1,100 Genmab shares on Nasdaq Copenhagen at an aggregated price of DKK 1,810.10 per share. Individual trades were carried out at prices between DKK 1,810.00 and DKK 1,811.00. The disclosure is made under Article 19 of the EU Market Abuse Regulation and covers trading by a person discharging managerial responsibilities.